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BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine tumour of the skin that has been associated with a new
tumour virus, the MCC polyomavirus.
METHODS: To investigate whether MCC may have a shared aetiology with other cancers, we investigated the risk of second cancers
after the diagnosis of MCC using the national cancer registries in Denmark, Norway and Sweden.
RESULTS: The overall cancer incidence was increased among patients diagnosed with MCC compared with the general population in
these countries (79 secondary cancers total, Standardized Incidence Ratio (SIR) 1.38 (95% confidence interval (CI): 1.10–1.72); 49
secondary cancer in females, SIR 1.7 (95% CI: 1.29–2.25); 30 secondary cancers in males and SIR 1.05 (95% CI: 0.73-1.5)). There
were significantly increased incidence ratios for non-melanoma skin cancers (34 secondary cancers, SIR 8.35 (95% CI: 5.97–11.68)),
melanoma of skin (6 secondary cancers, SIR 4.29 (95% CI: 1.93–9.56)) and laryngeal cancer (2 secondary cancers, SIR 9.51 (95% CI:
2.38–38)). The SIRs for these three cancer sites were also elevated on restricting the follow-up to cancers occurring at least one year
after MCC diagnosis.
CONCLUSIONS: Patients diagnosed with MCC are at increased risk of a second cancer, particularly, other skin cancers. Conceivable
explanations include the impact of increased surveillance of the skin and shared causative factors, for example, ultraviolet light
exposure or MCC polyomavirus infection.
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Merkel cell carcinoma (MCC) is a rare and aggressive neuroendo-
crine cutaneous tumour of the skin (Howard et al, 2006; Liao
2008). Incidence rates for MCC are age dependent and increase
dramatically after the age of 50 years (Hussain et al, 2010). Merkel
cell carcinoma harbours a newly discovered tumour virus, the
MCC polyomavirus (MCV) (Feng et al, 2008) in the majority of
cases (Feng et al, 2008; Kassem et al, 2008; Duncavage et al, 2009).
MCC polyomavirus is clonally integrated in MCC tumours
(Duncavage et al, 2009).
The epidemiology of MCV infection is as yet not known, and
bidirectional evaluation of whether patients with MCV-associated
disease are at excess risk of other diseases may provide important
clues that generate hypotheses for further study. Howard et al,
2006 evaluated the reciprocal risks of multiple primary cancers
among patients with MCC and significant associations were
reported for cancers of the salivary gland, brain and other organs
and unspecified parts of biliary tract, as well as multiple myeloma,
chronic lymphocytic leukaemia and NHL (Howard et al, 2006).
The Finnish Cancer Registry reported significantly increased risks
for basal cell carcinoma of the skin and chronic lymphocytic
leukaemia after the diagnosis of MCC (Koljonen et al, 2010).
Associations may in part be explained by aetiological factors
shared between MCC and other tumour types and MCV infection
could be one of these factors (Koljonen et al, 2010). However, to
avoid epidemiological biases, such as selection bias or chance
findings, large studies based on quality-assured and comparable
data sets from population-based cancer registries are preferable.
We used the nationwide Danish, Norwegian and Swedish Cancer
Registries to investigate the risk of developing second primary
cancer after the diagnosis of MCC. The data from these Registries
are based on mandatory notification and multiple sources and
have been evaluated as accurate and close-to-complete (Mattsson
et al, 1984; Tulinius et al, 1992; Storm et al, 1997; Larsen et al,
2009). In addition, the vast majority of cancers registered are based
on histological diagnosis, creating a reliable basis for assessment of
the risk of second cancers following the diagnosis of MCC
(Koljonen et al, 2010).
MATERIALS AND METHODS
Population-based national cancer registries were established in the
Nordic countries in the 1940 and 1950s, and are considered to have
a consistently high degree of comparability and completeness over
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ytime (Mattsson et al, 1984; Tulinius et al, 1992; Storm et al, 1997;
Larsen et al, 2009). Patients with a first primary cutaneous MCC
and other first primary cancer were identified from Danish,
Norwegian and Swedish population-based cancer registries.
The study cohort includes all persons who had been registered
with MCC over the calendar period of 1980–2007 in Denmark and
during 1990–2007 in Norway and Sweden. The follow-up started
on the date of the diagnosis of MCC and ended on the date of
death, emigration or the closing date of the study (31 December
2007), whichever occurred first. Cancers occurring within
6 months of MCC diagnosis, as well as secondary MCC following
primary MCC, were excluded from the analysis.
The observed subsequent primary cancers, occurring at least
6 months or at least 1 year after MCC diagnosis, were compared
with those expected by incidence rates among the national
populations. To estimate the expected number of cancers, the
age-, sex- period- and site-specific incidence rates (extracted from
NORDCAN) were multiplied by the respective numbers of
accumulated person-years at risk. The ratios of the observed-to-
expected number of cases were expressed as the standardized
incidence ratio (SIR). Risks were also estimated stratified by the
time that had passed since diagnosis of MCC (6–12 months, 1–4
years and X5 years). 95% confidence intervals (CIs) of the SIRs
were computed assuming a Poisson distribution for observed
cases. Findings were considered significant for a two-tailed test
with significance level Po0.05.
RESULTS
A total of 756 individuals were diagnosed with MCC, of which 716
had MCC as a first cancer (Table 1). Four subjects had MCCs
detected simultaneously with another cancers and 36 subjects had
MCCs after another cancer. None of these 40 patients had any
additional cancers after 6 months since MCC diagnosis. All MCC
diagnoses were based on histological examination. In total 23 of
them were diagnosed before the year 1992. Only 10 patients were
younger than 45 years at the time of the diagnosis, whereas 530
were 75 years of age or older. More patients were female (n¼442,
60%), resulting in a female to male ratio of 1.4:1. The mean
follow-up time after the diagnosis of MCC was 3.5 years. The
cumulative post-diagnosis follow-up time yielded 2632.5 person-
years at risk (Table 1).
Following a diagnosis of MCC, 142second primary cancers were
diagnosed in the study cohort. In total 79 and 65second primaries
were diagnosed after 6 months and 1 year, respectively, since MCC
diagnosis. The most frequent second primary cancer was non-
melanoma of the skin followed by melanoma of skin, breast
cancer, lung cancer and rectal cancer (Tables 2 and 3).
Patients diagnosed with MCC had a greater risk for a second
primary cancer than expected in a gender-, age- and calendar
period-matched general population. The overall SIR for any
subsequent cancer at any site, occurring at least after 6 months,
was 1.38 (95% CI: 1.1–1.72). Female MCC patients were diagnosed
with 49 subsequent cancers (SIR 1.7 (95% CI: 1.29–2.25)) and male
patients with 30 cancers (SIR 1.05 (95% CI: 0.73–1.5)).
The most frequent second primary cancer was non-melanoma
skin cancer (n¼34; SIR 8.35 (95% CI: 5.97–11.68)). The risks of
melanoma of skin (n¼6; SIR 4.29 (95% CI: 1.93–9.56)) and
laryngeal cancers (n¼2; SIR 9.51 (95% CI: 2.38–38)) were also
significantly increased (Table 2). These risks were significantly
Table 1 Numbers of patients diagnosed with MCC and the person-
years at risk for a second cancer stratified by age and sex
Number of subjects
diagnosed with MCC
Age at
diagnosis
Males Females Total Person-years at risk
following the MCC diagnosis
o29 1 1 2 25.6
30–44 2 6 8 74.3
45–59 18 17 35 157
60–74 83 98 181 862.4
475 210 320 530 1513
Total 314 442 756 2632.5
Abbreviation: MCC¼merkel cell carcinoma.
Table 4 Overall secondary cancers stratified by follow-up
Follow-up Observed Expected SIR (95% CI)
6–12 months 14 6.08 2.3 (1.36–3.89)
1–4 years 41 9.14 4.49 (3.3–6.09)
X5 years 24 8.91 2.69 (1.8–4.02)
Abbreviations: CI¼confidence interval; SIR¼standardized incidence ratio.
Table 3 Secondary cancers occurring at least 1 year after a MCC
diagnosis
Cancer site Observed Expected SIR (95% CI)
All types 65 57.4 1.13 (0.89–1.44)
Non-melanoma of the skin 27 4.07 6.63 (4.55–9.67)
Female breast 5 4.91 1.02 (0.42–2.45)
Colorectal 5 7.88 0.63 (0.26–1.53)
Lung 5 4.13 1.21 (0.5–2.91)
Melanoma of skin 5 1.4 3.58 (1.49–8.6)
Prostate 3 7.72 0.39 (0.13–1.2)
Bladder etc. 3 3.19 0.94 (0.3–2.92)
Larynx 2 0.21 9.51 (2.38–38.04)
Brain central nervous system 1 0.84 1.19 (0.17–8.44)
Kidney 1 0.91 1.1 (0.15–7.79)
Liver 1 0.52 1.94 (0.27–13.74)
Leukaemia 1 1.15 0.87 (0.12–6.17)
Non-Hodgkin lymphoma 1 1.43 0.7 (0.1–4.97)
Other female genital organs 1 0.34 2.94 (0.41–20.9)
Ovary etc. 1 1.46 0.69 (0.1–4.87)
Abbreviations: CI¼confidence interval; MCC¼merkel cell carcinoma.
Table 2 Secondary cancers occurring at least 6 months after an MCC
diagnosis
Cancer site Observed Expected SIR (95% CI)
All types 79 57.4 1.4 (1.1–1.72)
Non-melanoma of the skin 34 4.07 8.4 (5.97–11.68)
Female breast 6 4.91 1.2 (0.55–2.72)
Colorectal 6 7.88 0.8 (0.34–1.7)
Melanoma of skin 6 1.4 4.3 (1.93–9.56)
Lung 5 4.13 1.2 (0.5–2.91)
Prostate 3 7.72 0.4 (0.31–1.2)
Bladder etc. 3 3.19 0.9 (0.3–2.92)
Leukaemia 3 1.15 2.6 (0.84-8.09)
Larynx 2 0.21 9.5 (2.38–38.04)
Brain central nervous system 1 0.84 1.2 (0.17–8.44)
Kidney 1 0.91 1.1 (0.15–7.79)
Liver 1 0.52 1.9 (0.27–13.74)
Non-Hodgkin lymphoma 1 1.43 0.7 (0.1–4.97)
Other female genital organs 1 0.34 2.9 (0.41–20.9)
Ovary etc. 1 1.46 0.7 (0.1–4.87)
Abbreviations: CI¼confidence interval; MCC¼merkel cell carcinoma; SIR¼stand-
ardized incidence ratio.
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1 year after MCC diagnosis (Table 3). Stratification of follow up
time did not markedly affect the overall risk of second primary
cancers (Table 4).
DISCUSSION
We found that MCC patients were at increased risk of second
primary cancers, in particular for non-melanoma and melanoma
skin cancers. There was also a significantly increased risk for
laryngeal cancers, but this was based on small numbers. Previously
two registry-based studies have investigated the cancer risks among
patients diagnosed with MCC (Howard et al, 2006; Koljonen et al,
2010). In the SEER program in the United States (Howard et al,
2006), the risk of overall second malignancy after MCC diagnosis was
1.2 (95% CI: 1.0–1.5). There were also significantly elevated SIRs for
salivary gland tumours, biliary tract cancer and non-Hodgkin
lymphoma. In the Finnish Cancer Registry (Koljonen et al, 2010),
the SIRs for cancers at any site after MCC diagnosis was 2.3 (95% CI:
1.6–3.3). The SIRs of basal cell carcinoma and chronic lymphocytic
leukaemia showed significantly increased risk among MCC patients
(Koljonen et al, 2010). Selection/surveillance biases, different
qualities of different cancer registries, rare cancers and/or unstable
findings are conceivable explanations for the fact that the three
different studies have failed to identify the same cancer forms as the
most frequently occurring secondary primaries following MCC
diagnoses.
The small number of patients with other cancers occurring before
or on the same date as MCC preclude a more detailed analysis of
whether any cancer forms are linked also in the other direction, that
is, whether MCC risks are increased after other cancer. However, it is
interesting to note that not less than 26 out of the 40 other cancers
occurring before or on the same date as MCC were non-melanoma
skin cancers, suggesting that the link between MCC and non-
melanoma skin cancer may be bidirectional.
Shared aetiological factors which may conceivably explain the
increased risk of a second primary cancer after the diagnosis of
MCC include exposure to ultraviolet-radiation, immunosuppres-
sion or MCV infection. Exposure to sunlight may be an
explanation of concomitant associations of MCC, non-melanoma
skin cancer and melanoma. Also, MCV DNA is reported to be
frequently found in the skin, not only in MCC tissue (Feng et al,
2008; Becker et al, 2009), and involvement of MCV infection also in
other skin diseases is, therefore, plausible.
Surveillance bias after diagnosis should always be considered as
an explanation for excess risk of secondary cancers. Analysis of
trends of excess risks over time after diagnosis is conventionally
used to search for surveillance bias, as medical attention is
intensified immediately after a cancer diagnosis. We excluded
cases occurring less than 6 months after MCC diagnosis in our
analysis and we also found limited changes in estimates by
restricting the study to cancers occurring greater than 1 year after
diagnosis. Thus, although we have no evidence for surveillance
bias, it still should be considered as a likely explanation of our
findings. Especially for skin cancers, there may be a prolonged
increased vigilance, not only from physicians but also from the
patients themselves. The fact that the excess risk of skin cancer
was essentially restricted to females is difficult to explain, but it is
conceivable that gender-related differences in skin surveillance
may exist.
The assessment of the risk for second cancers requires a large
study cohort and a long study time. MCC is a rare and aggressive
cancer associated with a poor prognosis. As it occurs mostly in
elderly patients, the numbers of person-years available for follow-
up is limited. Although we combined data from three countries, a
somewhat inadequate number of person-years of follow-up is still
a limitation of our study.
The major strength of our study is that the data are from cancer
registries of three Nordic countries. These population-based
cancer registries provide long-term national data that are
considered to be of comparably high quality, with the majority
of diagnoses among cases histologically confirmed (Tulinius et al,
1992).
We conclude that the incidence of second primary cancers is
increased among patients diagnosed with MCC compared with the
general population. Patients diagnosed with MCC are at an excess
risk for malignant melanoma, larynx cancer and, in particular, for
non-melanoma skin cancer.
REFERENCES
Becker J, Houben R, Ugurel S, Trefzer U, Pfohler C, Schrama D (2009) MC
polyomavirus is frequently present in Merkel cell carcinoma of European
patients. J Invest Dermatol 129: 248–250
Duncavage E, Zehnbauer BA, Pfeifer JD (2009) Prevalence of merkel cell
polyomavirus in merkel cell carcinoma. Mod Pathol 22: 516–521
Feng H, Shuda M, Chang Y, Moore PS (2008) Clonal integration of a
polyomavirus in human merkel cell carcinoma. Science 319: 1096–1100
Howard R, Dores GM, Curtis RE, Anderson WF, Travis LB (2006) Merkel
cell carcinoma and multiple primary cancers. Cancer Epidemiol
Biomarkers Prev 15: 1545–1549
Hussain S, Sundquist J, Hemminki K (2010) Incidence trends of squamous
cell and rare skin cancers in the swedish national cancer registry point to
calendar year and age-dependent increases. J Invest Dermatol 130(5):
1323–1328
Kassem A, Schopflin A, Diaz C, Weyers W, Stickeler E, Werner M,
Zur Hausen A (2008) Frequent detection of Merkel cell polyomavirus in
human Merkel cell carcinomas and identification of a unique deletion in
the VP1 gene. Cancer Res 68: 5009–5013
Koljonen V, Kukko H, Tukiainen E, Bo ¨hling T, Sankila R, Joensuu H,
Pukkala E (2010) Second cancers following the diagnosis of Merkel
cell carcinoma: A nationwide cohort study. Cancer Epidemiology 34:
62–65
Larsen I, Sma ˚stuen M, Johannesen TB, Langmark F, Parkin DM, Bray F,
Møller B (2009) Data quality at the Cancer Registry of Norway: An
overview of comparability completeness, validity and timeliness.
Eur J Cancer 45: 1218–1231
Liao P (2008) Merkel cell carcinoma. Dermatologic Therapy 21: 447–451
Mattsson B, Wallgren A (1984) Completeness of the Swedish cancer
register. Non-notifi ed cancer cases recorded on death certificates in
1978. Acta Radiol Oncol 23: 305–313
Storm H, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish
Cancer Registry-history, content, quality and use. Dan Med Bull 44:
535–539
Tulinius H, Storm H, Pukkala E, Andersen A, Ericsson J (1992) Cancer in
the Nordic countries, 1981–86. A joint publication of the five Nordic
cancer registries. APMIS 100: 1–124
Second cancers after the diagnosis of merkel cell carcinoma
D Bzhalava et al
180
British Journal of Cancer (2011) 104(1), 178–180 & 2011 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y